Microbiota and Allergy (MATFA I)
Microbiota as Potential Target for Innovative Preventive and Therapeutic Strategies for Food Allergy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Naples, Italy, 80131
- Department of Traslational Medical Science - University of Naples Federico II
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Children with sure diagnosis of food allergy,
- children with sure diagnosis of respiratory allergy
Exclusion Criteria:
- age at enrollment <48 months or >84 months;
- eosinophilic disorders of the gastrointestinal tract;
- chronic systemic diseases;
- congenital cardiac defects;
- acute or chronic infections;
- autoimmune diseases;
- immunodeficiencies;
- chronic inflammatory bowel diseases;
- celiac disease;
- cystic fibrosis or other forms of primary pancreatic insufficiency;
- genetic and metabolic diseases;
- food intolerances;
- malignancy;
- chronic pulmonary diseases;
- malformations of the respiratory tract or of the gastrointestinal tract;
- pre-, pro- or sinbiotic use in the previous 3 months;
- antibiotics or gastric acidity inhibitors use in the previous 3 months.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Healthy controls
Healthy subjects
|
healthy controls
|
|
Food allergy
Childen with food allergy
|
food allergy
|
|
Respiratory allergy
Children with respiratory allergy
|
respiratory allergy
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Evaluation of gut microbiome features in allergic children and in healthy controls.
Time Frame: at enrollment
|
Comparatively evaluation of gut microbiome features in allegic children and in healthy controls.
|
at enrollment
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Gut microbiome and allergy disease course
Time Frame: at enrollment
|
Evaluation of gut microbiome influence on allergy disease course
|
at enrollment
|
|
Evaluation of gut microbiome features in children affected by different allergies (food and respiratory)
Time Frame: at enrollment
|
Comparatively evaluation of gut microbiome features in children with different allergies (food and respiratory)
|
at enrollment
|
|
Evaluation of gut microbiome features in children affected by different type of food allergy
Time Frame: at enrollment
|
Evaluation of gut microbiome features in children affected by different type of food allergy
|
at enrollment
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 02e14
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.